211 related articles for article (PubMed ID: 24127258)
1. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.
Coburn CA; Meinke PT; Chang W; Fandozzi CM; Graham DJ; Hu B; Huang Q; Kargman S; Kozlowski J; Liu R; McCauley JA; Nomeir AA; Soll RM; Vacca JP; Wang D; Wu H; Zhong B; Olsen DB; Ludmerer SW
ChemMedChem; 2013 Dec; 8(12):1930-40. PubMed ID: 24127258
[TBL] [Abstract][Full Text] [Related]
2. Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
Yu W; Coburn CA; Nair AG; Wong M; Tong L; Dwyer MP; Hu B; Zhong B; Hao J; Yang DY; Selyutin O; Jiang Y; Rosenblum SB; Kim SH; Lavey BJ; Zhou G; Rizvi R; Shankar BB; Zeng Q; Chen L; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Nomeir A; Kozlowski JA
Bioorg Med Chem Lett; 2016 Aug; 26(15):3800-5. PubMed ID: 27282742
[TBL] [Abstract][Full Text] [Related]
3. Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
Yu W; Coburn CA; Nair AG; Wong M; Rosenblum SB; Zhou G; Dwyer MP; Tong L; Hu B; Zhong B; Hao J; Ji T; Zan S; Kim SH; Zeng Q; Selyutin O; Chen L; Masse F; Agrawal S; Liu R; Xia E; Zhai Y; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Lin M; Kozlowski JA
Bioorg Med Chem Lett; 2016 Aug; 26(15):3414-20. PubMed ID: 27394665
[TBL] [Abstract][Full Text] [Related]
4. MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV.
Nair AG; Zeng Q; Selyutin O; Rosenblum SB; Jiang Y; Yang DY; Keertikar K; Zhou G; Dwyer M; Kim SH; Shankar B; Yu W; Tong L; Chen L; Mazzola R; Caldwell J; Tang H; Agrawal S; Liu R; Kong R; Ingravallo P; Xia E; Zhai Y; Nomeir A; Asante-Appiah E; Kozlowski JA
Bioorg Med Chem Lett; 2018 Jun; 28(10):1954-1957. PubMed ID: 29653894
[TBL] [Abstract][Full Text] [Related]
5. Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742.
Yu W; Zhou G; Coburn CA; Zeng Q; Tong L; Dwyer MP; Hu B; Zhong B; Hao J; Ji T; Zan S; Chen L; Mazzola R; Kim JH; Sha D; Selyutin O; Rosenblum SB; Lavey B; Nair AG; Heon Kim S; Keertikar KM; Rokosz L; Agrawal S; Liu R; Xia E; Zhai Y; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Chen S; Kozlowski JA
Bioorg Med Chem Lett; 2016 Oct; 26(19):4851-4856. PubMed ID: 27568086
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships of proline modifications around the tetracyclic-indole class of NS5A inhibitors.
Tong L; Yu W; Coburn CA; Chen L; Selyutin O; Zeng Q; Dwyer MP; Nair AG; Shankar BB; Kim SH; Yang DY; Rosenblum SB; Ruck RT; Davies IW; Hu B; Zhong B; Hao J; Ji T; Zan S; Liu R; Agrawal S; Carr D; Curry S; McMonagle P; Bystol K; Lahser F; Ingravallo P; Chen S; Asante-Appiah E; Kozlowski JA
Bioorg Med Chem Lett; 2016 Nov; 26(21):5354-5360. PubMed ID: 27680588
[TBL] [Abstract][Full Text] [Related]
7. Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.
Yu W; Coburn CA; Yang DY; Meinke PT; Wong M; Rosenblum SB; Chen KX; Njoroge GF; Chen L; Dwyer MP; Jiang Y; Nair AG; Selyutin O; Tong L; Zeng Q; Zhong B; Ji T; Hu B; Agrawal S; Xia E; Zhai Y; Liu R; Kong R; Ingravallo P; Asante-Appiah E; Nomeir A; Fells J; Kozlowski JA
Bioorg Med Chem Lett; 2016 Jul; 26(13):3158-3162. PubMed ID: 27180013
[TBL] [Abstract][Full Text] [Related]
8. Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development.
Nair AG; Zeng Q; Selyutin O; Rosenblum SB; Jiang Y; Yang DY; Keertikar K; Zhou G; Dwyer MP; Kim SH; Shankar B; Yu W; Tong L; Chen L; Mazzola R; Caldwell J; Tang H; Allard ML; Buckle RN; Gauuan PJ; Holst CL; Martin GS; Naicker KP; Vellekoop S; Agrawal S; Liu R; Kong R; Ingravallo P; Xia E; Zhai Y; Nomeir A; Kozlowski JA
Bioorg Med Chem Lett; 2016 Mar; 26(5):1475-9. PubMed ID: 26850003
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, biological evaluation and in silico modeling of novel pan-genotypic NS5A inhibitors.
Ivashchenko AA; Ivanenkov YA; Aladinskiy VA; Karapetian RN; Koryakova AG; Ryakhovskiy AA; Mitkin OD; Kravchenko DV; Savchuk NP; Zagribelnyy BA; Ivashchenko AV
Bioorg Med Chem; 2020 Oct; 28(20):115716. PubMed ID: 33069072
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent macrocyclic HCV NS5A inhibitors.
Yu W; Vibulbhan B; Rosenblum SB; Martin GS; Vellekoop AS; Holst CL; Coburn CA; Wong M; Selyutin O; Ji T; Zhong B; Hu B; Chen L; Dwyer MP; Jiang Y; Nair AG; Tong L; Zeng Q; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Fells J; Kozlowski JA
Bioorg Med Chem Lett; 2016 Aug; 26(15):3793-9. PubMed ID: 27282743
[TBL] [Abstract][Full Text] [Related]
11. The discovery of potent nonstructural protein 5A (NS5A) inhibitors with a unique resistance profile-Part 1.
Tran TD; Wakenhut F; Pickford C; Shaw S; Westby M; Smith-Burchnell C; Watson L; Paradowski M; Milbank J; Brimage RA; Halstead R; Glen R; Wilson CP; Adam F; Hay D; Chiva JY; Nichols C; Blakemore DC; Gardner I; Dayal S; Pike A; Webster R; Pryde DC
ChemMedChem; 2014 Jul; 9(7):1378-86. PubMed ID: 24729513
[TBL] [Abstract][Full Text] [Related]
12. Potent bisimidazole-based HCV NS5A inhibitors bearing annulated tricyclic motifs.
Zhong M; Peng E; Huang N; Huang Q; Huq A; Lau M; Colonno R; Li L
Bioorg Med Chem Lett; 2014 Dec; 24(24):5738-5742. PubMed ID: 25453811
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.
Tong L; Yu W; Chen L; Selyutin O; Dwyer MP; Nair AG; Mazzola R; Kim JH; Sha D; Yin J; Ruck RT; Davies IW; Hu B; Zhong B; Hao J; Ji T; Zan S; Liu R; Agrawal S; Xia E; Curry S; McMonagle P; Bystol K; Lahser F; Carr D; Rokosz L; Ingravallo P; Chen S; Feng KI; Cartwright M; Asante-Appiah E; Kozlowski JA
J Med Chem; 2017 Jan; 60(1):290-306. PubMed ID: 27808515
[TBL] [Abstract][Full Text] [Related]
14. Development of a New Structural Class of Broadly Acting HCV Non-Nucleoside Inhibitors Leading to the Discovery of MK-8876.
McComas CC; Palani A; Chang W; Holloway MK; Lesburg CA; Li P; Liverton N; Meinke PT; Olsen DB; Peng X; Soll RM; Ummat A; Wu J; Wu J; Zorn N; Ludmerer SW
ChemMedChem; 2017 Sep; 12(17):1436-1448. PubMed ID: 28741898
[TBL] [Abstract][Full Text] [Related]
15. Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors.
Dwyer MP; Keertikar KM; Chen L; Tong L; Selyutin O; Nair AG; Yu W; Zhou G; Lavey BJ; Yang DY; Wong M; Kim SH; Coburn CA; Rosenblum SB; Zeng Q; Jiang Y; Shankar BB; Rizvi R; Nomeir AA; Liu R; Agrawal S; Xia E; Kong R; Zhai Y; Ingravallo P; Asante-Appiah E; Kozlowski JA
Bioorg Med Chem Lett; 2016 Aug; 26(16):4106-11. PubMed ID: 27423481
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir.
Belema M; Nguyen VN; Bachand C; Deon DH; Goodrich JT; James CA; Lavoie R; Lopez OD; Martel A; Romine JL; Ruediger EH; Snyder LB; St Laurent DR; Yang F; Zhu J; Wong HS; Langley DR; Adams SP; Cantor GH; Chimalakonda A; Fura A; Johnson BM; Knipe JO; Parker DD; Santone KS; Fridell RA; Lemm JA; O'Boyle DR; Colonno RJ; Gao M; Meanwell NA; Hamann LG
J Med Chem; 2014 Mar; 57(5):2013-32. PubMed ID: 24521299
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons.
Belema M; Nguyen VN; Romine JL; St Laurent DR; Lopez OD; Goodrich JT; Nower PT; O'Boyle DR; Lemm JA; Fridell RA; Gao M; Fang H; Krause RG; Wang YK; Oliver AJ; Good AC; Knipe JO; Meanwell NA; Snyder LB
J Med Chem; 2014 Mar; 57(5):1995-2012. PubMed ID: 24437689
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants.
Yu W; Tong L; Hu B; Zhong B; Hao J; Ji T; Zan S; Coburn CA; Selyutin O; Chen L; Rokosz L; Agrawal S; Liu R; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Chen S; Kozlowski JA
J Med Chem; 2016 Nov; 59(22):10228-10243. PubMed ID: 27792320
[TBL] [Abstract][Full Text] [Related]
19. Finger-loop inhibitors of the HCV NS5b polymerase. Part 1: Discovery and optimization of novel 1,6- and 2,6-macrocyclic indole series.
McGowan D; Vendeville S; Lin TI; Tahri A; Hu L; Cummings MD; Amssoms K; Berke JM; Canard M; Cleiren E; Dehertogh P; Last S; Fransen E; Van Der Helm E; Van den Steen I; Vijgen L; Rouan MC; Fanning G; Nyanguile O; Van Emelen K; Simmen K; Raboisson P
Bioorg Med Chem Lett; 2012 Jul; 22(13):4431-6. PubMed ID: 22542193
[TBL] [Abstract][Full Text] [Related]
20. Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
Chen CM; He Y; Lu L; Lim HB; Tripathi RL; Middleton T; Hernandez LE; Beno DW; Long MA; Kati WM; Bosse TD; Larson DP; Wagner R; Lanford RE; Kohlbrenner WE; Kempf DJ; Pilot-Matias TJ; Molla A
Antimicrob Agents Chemother; 2007 Dec; 51(12):4290-6. PubMed ID: 17908950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
